Think of it as setting the stage for a successful performance
(2022) found that treatments with Liraglutide and Semaglutide resulted in weight reductions ranging from 48.2% to 88.7%, showcasing the impressive weight loss potential of these medications in obese or overweight adults without diabetes
Unblinding Unblinding of the participants will be permissible under the following circumstances: treatment of a participant in a medical emergency that requires knowledge of treatment allocation, treatment of a participant for an adverse event (AE), in the event of a suspected unexpected serious adverse reaction (SAR), and SAR is defined as any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity or is a congenital anomaly or birth defect
However, the cardiovascular outcome trials that have been completed so far have failed to show cardioprotection with DPP-4 inhibitor treatment, which might be partly attributable to limitations of the study design, patient selection and trial duration
